Dimensions change and left ventricular function carvedilol post therapy due to heart failure cases in children with congenital heart disease left-to-right
  • Article Type: Research Article
  • Eurasian Journal of Biosciences, 2020 - Volume 14 Issue 2, pp. 3697-3701
  • Published Online: 30 Sep 2020
  • Open Access Full Text (PDF)

Abstract

Background: Congenital Heart Disease (CHD) is the most common congenital disorder in newborns with a prevalence of 9.1 per 1000 live births. In left-to-right PJB shunts occur excessive volume burden on the ventricles, resulting in heart failure.
Purpose: Knowing the difference in changes in the dimensions and function of the left ventricle on echocardiography after standard therapy plus placebo with the standard therapy group plus carvedilol in children with heart failure due to left-to-right CHD.
Method: Using a Randomized Controlled Trial (RCT) research design by giving a Double Blind Study treatment. Research data including comparison of initial data and final data of the two groups were analyzed by independent sample t test.
Result: The results of measurement of left ventricular mass showed a significant decrease to 40.56 ± 23.63 g / m2 (p <0.001). There was a significant decrease in left ventricular volume to 42.23 ± 20.36 m3 (p = 0.05). There was a significant increase in the mean left ventricular ejection fraction to 74.16 ± 4.10% (p = 0.03). There was an increase in the left ventricular shortening fraction to 42.18 ± 3.66% (p = 0.04).
Conclusion: There are differences in the dimensions of the left ventricular at the end of systolic (DVKI-AS), the left ventricle at the end of diastolic (VKI-AD), the thickness of the back wall of the left ventricle at the end of diastolic (DBVKI-AD), and the thickness of the interventricular septum at the end of diastolic (SIV-AD).

References

  • Aziz, A. S., Sigit, R., Basuki, A., & Hidayat, T. (2018). Cardiac motions classification on sequential PSAX echocardiogram. Indones. J. Electr. Eng. Comput. Sci., 12(3), 1289-1296.
  • Bergström, A., Andersson, B., Edner, M., Nylander, E., Persson, H., & Dahlström, U. (2004). Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler‐echocardiographic study (SWEDIC). European journal of heart failure, 6(4), 453-461.
  • Clausen, E. (2018). Probable Deep Erosion by Continental Ice Sheet Melt Water Floods: Chalk Buttes Area of Carter County, Montana, USA. International Journal of Geography and Geology, 7(1), 14-26.
  • Conrad, N., Judge, A., Canoy, D., Tran, J., O’Donnell, J., Nazarzadeh, M., ... & Rahimi, K. (2019). Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: A cohort study of 93,000 UK patients. PLoS medicine, 16(5), e1002805.
  • Foerster, S. R., & Canter, C. E. (2008). Pediatric heart failure therapy with β-adrenoceptor antagonists. Pediatric Drugs, 10(2), 125-134.
  • Hsu, D. T., & Pearson, G. D. (2009). Heart failure in children: part II: diagnosis, treatment, and future directions. Circulation: Heart Failure, 2(5), 490-498.
  • Kantor, P. F., & Mertens, L. L. (2010). Clinical practice: heart failure in children. Part II: current maintenance therapy and new therapeutic approaches. European journal of pediatrics, 169(4).
  • Kay, J. D., Colan, S. D., & Graham, T. P. (2001). Congestive heart failure in pediatric patients. The American heart journal, 142(5), 923-928.
  • Khattar, R. S., Senior, R., Soman, P., van der Does, R., & Lahiri, A. (2001). Regression of left ventricular remodeling in chronic heart failure: comparative and combined effects of captopril and carvedilol. American heart journal, 142(4), 704-713.
  • Kusumastuti, N. P., & Osaki, M. (2015). Electric velocimetry and transthoracic echocardiography for non-invasive cardiac output monitoring in children after cardiac surgery. Crit Care, 18(2), 37.
  • Lechat, P. (2006). The evolution of heart failure management over recent decades: from CONSENSUS to CIBIS. European Heart Journal Supplements, 8(suppl_C), C5-C12.
  • Nishiyama, M., Park, I. S., Yoshikawa, T., Hatai, Y., Ando, M., Takahashi, Y., ... & Murakami, Y. (2009). Efficacy and safety of carvedilol for heart failure in children and patients with congenital heart disease. Heart and vessels, 24(3), 187-192.
  • Nolan, J. P., Neumar, R. W., Adrie, C., Aibiki, M., Berg, R. A., Böttiger, B. W., ... & Kern, K. B. (2008). Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication: a scientific statement from the International liaison Committee on Resuscitation; the American Heart Association Emergency cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on cardiopulmonary, Perioperative, and Critical Care; the Council on clinical cardiology; the Council on Stroke. Resuscitation, 79(3), 350-379.
  • Pavo, I. J., & Michel-Behnke, I. (2017). Clinical cardiac regenerative studies in children. World Journal of Cardiology, 9(2), 147.
  • Remme, W., & Swedberg, K. (2001). Guidelines for the diagnosis and treatment of chronic heart failure. European heart journal, 22(17), 1527-1560.
  • Spicer, R. L. (2001). Carvedilol—a new dimension in pediatric heart failure therapy. The Journal of pediatrics, 138(4), 457-458.
  • van der Linde, D., Konings, E. E., Slager, M. A., Witsenburg, M., Helbing, W. A., Takkenberg, J. J., & Roos-Hesselink, J. W. (2011). Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. Journal of the American College of Cardiology, 58(21), 2241-2247.
  • Wahab, A.S. K.D. (2009). Congestive heart failure. In: Susanto D, editor. Child cardiology: congenital heart disease that is not cyanotic. 1st ed. Jakarta: EGC; 271–94 p.
  • Widiyanti, P., Paramadini, A. W., Jabbar, H., Fatimah, I., Nisak, F. N., & Puspitasari, R. A. (2016, March). Morphology characterization and biocompatibility study of PLLA (Poly-L-Llactid-Acid) coating chitosan as stent for coronary heart disease. In AIP Conference Proceedings (Vol. 1718, No. 1, p. 060008). AIP Publishing LLC.

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.